Neurorehabilitation firm Lifeward's Q3 revenue falls 12% as ReWalk sales decline

Overview

• Israel-US neurorehabilitation firm's Q3 revenue fell 12% yr/yr as ReWalk sales declined

• AlterG product revenue rose 18%, driven by higher US shipments and service revenue

Outlook

• Company expects channel-partner model to expand ReWalk access and support long-term revenue growth

• Lifeward says broad reimbursement access positions partners to reach more eligible ReWalk patients

• Company is developing AI-enabled rehabilitation technologies and exploring new AI capabilities

Result Drivers

• ALTERG GROWTH - AlterG revenue rose 18% on higher U.S. unit shipments, increased service revenue, and improved average selling prices

• REWALK SALES DECLINE - ReWalk revenue fell due to transition to channel-partner distribution model, which affected timing of sales

• HIGHER COSTS AND ACQUISITION EXPENSES - Gross margin declined due to adverse foreign exchange, higher freight costs, tariffs, and revenue sharing expense from Oratech acquisition

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Reuters Recommended Reads

• Nov 10 - Israel's ICL Group Q3 sales, net income rise on diversified portfolio

• Nov 11 - Israel's InMode Q3 revenue slightly beats estimates on Asia growth

• Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)